Jw Therapeutics 药明巨诺

Jw Therapeutics 药明巨诺 company information, Employees & Contact Information

JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.

Company Details

Employees
107
Founded
-
Address
浦东新区金科路4560号金创大厦3号楼2层, 上海,上海 201210,china
Phone
+ 86-21-50464201
Industry
Biotechnology
Keywords
Manager jobs.
HQ
上海, 上海
Looking for a particular Jw Therapeutics 药明巨诺 employee's phone or email?

Jw Therapeutics 药明巨诺 Questions

News

JW Therapeutics’ Relma-Cell Approved in China for R/R Mantle Cell Lymphoma - CGTLive®

JW Therapeutics’ Relma-Cell Approved in China for R/R Mantle Cell Lymphoma CGTLive®

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX - PR Newswire

Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX PR Newswire

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China - Business Wire

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China Business Wire

JW Therapeutics rakes in $300M Hong Kong IPO to bring CAR-Ts to China - Fierce Biotech

JW Therapeutics rakes in $300M Hong Kong IPO to bring CAR-Ts to China Fierce Biotech

JW Therapeutics launches $300M IPO in Hong Kong, targets first CAR T approval in China - BioWorld MedTech

JW Therapeutics launches $300M IPO in Hong Kong, targets first CAR T approval in China BioWorld MedTech

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug - Labiotech.eu

JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug Labiotech.eu

JW Therapeutics Announces New Phase 2 Trial of Relma-Cel in Large B-cell Lymphoma - CGTLive®

JW Therapeutics Announces New Phase 2 Trial of Relma-Cel in Large B-cell Lymphoma CGTLive®

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma - BioSpace

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma BioSpace

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies - GlobeNewswire

Acepodia and JW Therapeutics Enter into Option and License Agreement for Off-the-shelf NK Cell Therapies GlobeNewswire

JW Therapeutics accelerates R&D of T cell-based immunotherapies in China - BioSpectrum Asia

JW Therapeutics accelerates R&D of T cell-based immunotherapies in China BioSpectrum Asia

Bluebird spinout 2seventy bio, JW Therapeutics ink $3M deal for solid tumor cell therapy program - Fierce Biotech

Bluebird spinout 2seventy bio, JW Therapeutics ink $3M deal for solid tumor cell therapy program Fierce Biotech

JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A - Fierce Biotech

JW Therapeutics, a China CAR-T biotech formed by Juno and WuXi, gains $90M series A Fierce Biotech

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant